Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to -$2.4 billion.

  • Astrazeneca's Other Accumulated Expenses fell 3440.68% to -$2.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.4 billion, marking a year-over-year decrease of 3440.68%. This contributed to the annual value of -$2.4 billion for FY2025, which is 3440.68% down from last year.
  • As of Q4 2025, Astrazeneca's Other Accumulated Expenses stood at -$2.4 billion, which was down 3440.68% from -$2.0 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Other Accumulated Expenses registered a high of -$1.6 billion during Q2 2025, and its lowest value of -$5.2 billion during Q2 2021.
  • Its 5-year average for Other Accumulated Expenses is -$3.2 billion, with a median of -$2.6 billion in 2023.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 5403.52% in 2023, then plummeted by 3440.68% in 2025.
  • Astrazeneca's Other Accumulated Expenses (Quarter) stood at -$4.9 billion in 2021, then increased by 13.44% to -$4.3 billion in 2022, then skyrocketed by 37.7% to -$2.7 billion in 2023, then skyrocketed by 33.46% to -$1.8 billion in 2024, then crashed by 34.41% to -$2.4 billion in 2025.
  • Its Other Accumulated Expenses stands at -$2.4 billion for Q4 2025, versus -$2.0 billion for Q3 2025 and -$1.6 billion for Q2 2025.